Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer
- 31 January 2003
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 39 (1) , 77-84
- https://doi.org/10.1016/s0169-5002(02)00387-2
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Paclitaxel and G-CSF in Previously Untreated Patients With Extensive Stage Small-Cell Lung CancerAmerican Journal of Clinical Oncology, 1999
- Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell linesCancer Chemotherapy and Pharmacology, 1998
- A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancerBritish Journal of Cancer, 1998
- Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.Journal of Clinical Oncology, 1997
- Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.Journal of Clinical Oncology, 1995
- Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.Journal of Clinical Oncology, 1995
- Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancerAnnals of Oncology, 1994
- Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristineZeitschrift für Krebsforschung und Klinische Onkologie, 1993
- Sequences of taxol and cisplatin: a phase I and pharmacologic study.Journal of Clinical Oncology, 1991
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989